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Abstract  
Introduction: Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase that plays a role in 
atherosclerotic plaque destabilization. In recent studies, insulin-like growth factor-1 (IGF-1) has been 
introduced as a mediator of atherosclerosis. PAPP-A and IGF-1 level may be important diagnostic indicators of 
acute coronary syndrome (ACS).  
Objective: The present study tried to assess the diagnostic role of IGF-1 and PAPP-A biomarkers in ACS 
spectrum. 
Methods: The serum level of IGF-1, PAPP-A and troponin I was determined in 121 consecutive patients with 
ACS. Relationships were assessed by t-test, ANOVA and the non-parametric equivalent. Accuracy of biomarkers 
was measured by the area under the ROC curve (AUC) and optimal cut-off points to diagnose STEMI and 
NSTEMI using Youden index. 
Results: In patients with acute ST segment elevation myocardial infarction (STEMI), all of these three 
biomarkers were significantly higher than those in patients with unstable angina (P= 0.028 for IGF-1, P<0.001 
for PAPP-A and Troponin-I). Mean level of IGF-1 in patients with renal failure was significantly higher than that 
in patients without renal failure (137.9±35.1 vs 105.1±46.9, P=0.003), but PAPP-A and serum Troponin-I level 
had no significant difference in renal failure groups (P>0.05).  ROC curve analysis showed that after Troponin-
I, PAPP-A was a good discriminator between patients with STEMI and patients with unstable angina 
(AUC=0.79). Optimum cut-off value for PAPP-A was found to be 89.2 ng/ml, with sensitivity and specificity of 
66.7% and 83.8%, respectively. 
Conclusion: PAPP-A can be a novel biomarker for both identification of patients with STEMI and risk 
stratification in patients with ACS. 
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INTRODUCTION
Insulin-like growth factor-1 (IGF-1) and 
pregnancy-associated plasma protein-A (PAPP-
A) are two biomarkers that have been recently 
considered in the management of patients with 
acute coronary syndrome (ACS).  
IGF-1 is a functional encoded protein produced by 
IGF-1 gene. IGF-1 has been shown to oppose 
endothelial dysfunction by interacting with 
endothelial binding sites leading to nitric oxide 
production (1, 2). Also, IGF-1 has some anti-
inflammatory and vasodilation properties that 
result in coronary flow preservation (3). Moreover, 
the atherogenicity effect of IGF-1 has been 
suggested due to its potential role to induce 
vascular smooth muscle cell (VSMC) proliferation 
leading to arterial obstructive lesions (4, 5). 
However, there are still conflicting results 
concerning IGF-1 and coronary artery diseases. 
Some studies suggested that a decreased level of 
IGF-1 in patient with ST segment elevation 
myocardial infarction (STEMI) can be used as a 
diagnostic marker of myocardial necrosis (6, 7). 
Conversely, some randomized trials reported 
diagnostic importance of an increased level of IGF-
1 in the setting of stent restenosis and lowering 
IGF-1 levels with somatostatin analogues such as 
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angiopeptin (8, 9). 
PAPP-A is a human protein encoded by PAPP-
A gene (10). This agent is a zinc binding 
metalloproteinase which splits IGF binding 
proteins (IGFBPs) especially IGFBP-4, therefore 
with increasing IGFs allowing their actions (11). 
Circulating PAPP-A has recently been suggested as 
an independent predictor of next and late adverse 
cardiovascular events. Moreover, increased 
activity of PAPP-A has been reported in ACS, hence 
it is a promising biomarker for risk stratification in 
these patients (12-15). Clinically, an increase in 
serum level of PAPP-A has been shown in patients 
with ACS that may be an indicator for coronary 
plaques complexity and vulnerability (16). In fact, 
higher levels of PAPP-A were found in cells and 
extracellular matrix of the plaques that showed 
rupture or erosion compared to stable plaques 
(12). Despite evidence on the potential role of IGF-
1 and PAPP-A as a precursor for stimulating or 
preserving coronary flow and cardiac function, 
whether the plasma levels of these two biomarkers 
provide diagnostic information in patients with 
coronary lesions has remained unclear. The 
present study aimed to assess the diagnostic role of 
IGF-1 and PAPP-A biomarkers for a wide spectrum 
of coronary artery diseases and their correlation 
with conventional cardiovascular risk factors.  
METHODS 
Study design and participants 
This cross-sectional study was conducted from 
2009 until 2010 in Imam Khomeini Hospital of 
Naghade, affiliated with Urmia University of 
Medical Science, West Azerbaijan Province. The 
study was approved by the Institutional Ethics 
Committee and written informed consent was 
obtained from the study population. 
Study population 
All patients diagnosed as ACS based on the 
American College of Cardiology guideline 
definitions by considering troponin levels, ECG 
abnormalities and clinical context (17); 
hospitalized in cardiac and critical care unit, 
admitted within one hour after the onset of chest 
pain were eligible. ACS was diagnosed based on the 
latest guideline of American College of Cardiology 
released on 2014 (especially by serum level of 
troponin I) (17-19). The exclusion criteria were 
progressive and serious systemic disorders such as 
liver diseases, overt heart failure, history of major 
surgeries, pregnancy, known infectious or 
inflammatory disorders, or malignancies. Sampling 
was conducted prospectively and consecutively. A 
total of 145 patients were admitted during the 
study and 18 were excluded due to the exclusion 
criteria and 6 were excluded due to incomplete lab 
data. Finally, 121 patients were included for the 
analysis. 
Definitions 
ACS is a spectrum of conditions from unstable 
angina (UA) to STEMI. UA is a condition in which 
biomarkers like troponin do not increase. 
Inversely, myocardial infarction leads to an 
increase in troponin. According to the American 
college of cardiology, STEMI is a condition defined 
with ST segment elevation plus a rise in troponin I 
levels above > 0.5 ng/mL and NSTEMI is described 
with positive troponin levels without ST segment 
elevation (20, 21). Patients were categorized with 
eGFR lower than 90 mL/min/1.73 m2 as chronic 
kidney disease (CKD) (22). Left ventricular systolic 
dysfunction (LVSDF) is qualitatively categorized to 
severe (<30%), moderate (30-40%), mild (40-
50%) and preserved (>50%) stages (23). 
Data gathering  
Baseline characteristics including demographics, 
medical history, and troponin indices were 
collected from hospital records and approved by 
two cardiologists using a pre-designed checklist. 
Venous blood samples were taken from each 
patient within three hours after the onset of chest 
pain for routine tests and for measuring serum 
level of IGF-1 and PAPP-A. Serum level of IGF-1 was 
determined by the DEMEDITEC IGF-1 600 ELISA 
Kit (Enzyme-Linked Immunosorbent Assay). 
Standard range was defined according to the 
manufacturer’s protocol 10 – 600 ng/ml. The 
DEMEDITEC PAPP-A US ELISA Kit was also used for 
PAPP-A assay based on the sandwich principle. The 
assay ranged 0-450 ng/ml. To minimize inter-
observer variability, all measurements were 
followed by a single researcher.   
Data analysis 
Results are presented as mean ± standard 
deviation (SD) and median [Interquartile range 
(IQR)] for quantitative variables and summarized 
by absolute frequencies and percentages for 
categorical variables. Quantitative variables are 
also compared with independent t-test for two 
groups and one-way ANOVA for more than two 
groups. We used Mann-Whitney U and Kruskal-
Wallis H test for variables with non-normal 
distribution. Post hoc analysis and correction of 
error type-I in multiple comparisons were 
conducted based-on Bonferroni method. Spearman 
correlation test was applied to determine the 
correlation between the level of IGF-1, PAPP-A 
biomarkers and Troponin-I. We used Shapiro-Wilk 
test and graphical approaches for assessing 
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normality.  
Accuracy of biomarkers was measured by the area 
under the ROC curve (AUC). ROC analysis was used 
to choose the optimal cut-off points to diagnose 
STEMI and NSTEMI using highest values of the 
Youden index and calculated sensitivity and 
specificity with 95% confidence interval (CI) for 
optimal cut-off points. Statistical significance was 
determined as a p value of ≤ 0.05. All statistical 
analyses were performed using SPSS software 
version 22.0 (Armonk, NY: IBM Corp) and STATA 
version 14 (Stata Corp LLC). 
RESULTS 
As shown in table 1, among 121 participants, their 
mean age was 69.09±13.00 years (range: 38 to 95 
years) and the majority of them (68%) were male. 
Of total patients, 25.4% were smokers and more 
than 20% had no risk factor of hypertension, 
hyperlipidemia or diabetes mellitus. Almost 56% of 
the patients with ACS had unstable angina, and 
severe left ventricle systolic dysfunction (LVSDF) 
was detected in 17.4% (Table 1).  
IGF-1 levels and demographic characteristics  
No difference was observed in the mean IGF-1 level 
(ng/ml) between men and women (115.0±48.3 vs 
102.6±42.2, p=0.173). Also, no difference was 
observed in serum level of IGF-1 between 
hypertensive and normotensive groups 
(112.3±40.2 vs 110.7±49.0, p=0.866), the groups 
with and without hyperlipidemia (107.1±46.0 vs 
112.2±47.0, p=0.618), smoker and non-smoker 
groups (117.3±48.9 vs 108.8 ±45.8, p=0.373), and 
also diabetics and non-diabetics (117.1±43.2 vs 
108.3±48.2, p=0.330). 
PAPP-A levels and Troponin I, and demographic 
characteristics  
PAPP-A level was significantly higher in male than 
in female patients [median (IQR): 70.0 (150.0) vs 
19.0 (77.0)]. Also, troponin I was higher in male 
than in female patients and this difference was 
marginally significant (p=0.054). PAPP-A levels 
and Troponin-I in patients with or without any risk 
factor was not significantly different (p>0.05) 
(Table 2).  
Biomarkers and LVSDF   
There were no significant differences in serum 
level of IGF-1 and PAPP-A, and outcome in terms of 
different stages of LVSDF (P=0.307 and p=0.792 
respectively). But Troponin-I was lower in mild 
LVSDF than moderate and severe LVSDF, and this 
difference was marginally significant (p=0.093) 
(Table 2). 
Correlation between IGF-1, PAPP-A and 
Troponin-I  
Our study showed direct significant correlation 
between troponin I and two parameters of IGF-1 
(r=0.29, p=0.001) and PAPP-A (r=0.40, p<0.001). 
Moreover, the correlation   between PAPP-A and 
IGF-1 indicators was direct and significant (r=0.29, 
p=0.001). 
Comorbidities and level of study biomarkers 
Twenty-two patients (18.2%) suffered renal 
failure. Mean level of IGF-1 in patients with renal 
failure was significantly higher than those without 
renal failure (137.9±35.1 vs 105.1±46.9, p=0.003). 
No difference was found in the level of PAPP-A and 
serum troponin I level between the patients with 
and without renal failure (p>0.05) (Table 2).  
Type of ACS and biomarkers  
All assessed biomarkers were significantly 
associated with the type of ACS (p<0.05). Mean 
serum level of IGF-1 was 132.1, 109.3 and 104.0 for 
STEMI, NSTEMI and UA, respectively (p=0.028). In 
post hoc analysis, a significant difference was 
observed just between UA and STEMI (p= 0.023) 
and the difference between NSTEMI and STEMI 
was not significant (p=0.221) (Table 2). 
The relationship of PAPP-A and troponin I with 
type of ACS was also significant (p<0.001). Post hoc 
analysis showed PAPP-A was significantly lower in 
UA compared to STEMI [Median (IQR): 12.8 (73.3) 
vs 116.0 (220.0); p<0.001] and NSTEMI [Median 
(IQR): 12.8 (73.3) vs 108.0 (128.0); p=0.003]. Also, 
post hoc analysis showed Troponin-I was 
significantly lower in UA compared to STEMI 
Table 1: Baseline characteristics of study population 
Variable Frequency (%) 
Gender  
Female 38 (31.4) 
Male 83 (68.6) 
Risk factors  
Hypertension 32 (24.6) 
Hyperlipidemia 26 (20) 
Smoker 33 (25.4) 
Diabetes mellitus 39 (30) 
Type of acute coronary syndrome  
Unstable angina 68 (56.2) 
NSTEMI 25 (20.7) 
Extensive anterior MI 10 (8.3) 
Inferior MI 12 (9.9) 
Anteroseptal MI 3 (2.5) 
Anterolateral MI 2 (1.7) 
LV systolic dysfunction  
Preserved EF 1 (0.8) 
Mild LVSDF 62 (51.2) 
Moderate LVSDF 37 (30.6) 
Severe LVSDF 21 (17.4) 
MI: Myocardial infarction; NSTEMI: Non-ST segment 
elevation myocardial infarction; LVEF: Left ventricular 
ejection fraction 
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[Median (IQR): 0.01 (0.02) vs 0.56 (2.6); p<0.001] 
and NSTEMI [Median (IQR): 0.01 (0.02) vs 0.18  
(1.1); p<0.001]. But differences of PAPP-A and 
troponin I level between STEMI and NSTEMI was 
not significant (p=0.155 and p=0.113, respectively) 
(Table 2). 
Accuracy of biomarkers to predict STEMI and 
NSTEMI  
In the ROC curve, biomarker levels were plotted for 
their ability to predict STEMI comparing patients 
with UA. AUC (95% CI) for IGF-1, PAPP-A and 
Troponin-I was 0.61 (0.48 to 0.74), 0.79 (0.69 to 
0.89), and 0.89 (0.82 to 0.96), respectively. So, IGF-
1 level was not able to predict STEMI comparing 
patients with UA (Figure 1). The optimum cut-off 
value for PAPP-A was found to be 89.2 ng/ml with 
67% sensitivity and 84% specificity. The optimum 
cut-off value for Troponin-I was found to be 0.086 
with 85% sensitivity and 87% specificity (Table 3).   
Also based-on ROC curve, biomarker levels were 
plotted for their ability to predict NSTEMI 
comparing patients with UA. AUC (95% CI) for IGF-
1, PAPP-A and Troponin-I was 0.50 (0.37 to 0.64), 
0.68 (0.55 to 0.82), and 0.86 (0.78 to 0.94), 
respectively. So, IGF-1 level was not able to predict 
NSTEMI comparing patients with UA and also, 
Table 2: Distribution and association of IGF-1, PAPP-A and Troponin-I with sex, risk factors, LVSDF, renal failure, type of ACS and 
type of STEMI 
Variable 
Insulin-like 
growth factor-1 p 
Pregnancy-associated 
plasma protein-A p 
Troponin-I 
p 
Mean (SD) Mean (SD) Mean (SD) 
Sex  
0.173 
 
0.002 
 
0.054 Male 115.0 (48.3) 134.2 (185.3) 0.88 (2.1) 
Female 102.6 (42.2) 48.3 (68.6) 0.35 (1.2) 
Hypertension  
0.866 
 
0.875 
 
0.939 Yes 112.3 (40.2) 100.2 (183.6) 0.76 (1.7) 
No 110.7 (49.0) 109.7 (155.8) 0.69 (1.9) 
Hyperlipidemia  
0.618 
 
0.830 
 
0.712 Yes 107.1 (46.0) 75.4 (84.7) 1.1 (3.0) 
No 112.2 (47.0) 115.9 (177.8) 0.61 (1.4) 
Smoker  
0.373 
 
0.123 
 
0.219 Yes 117.3 (48.9) 134.0 (174.4) 1.1 (2.8) 
No 108.8 (45.8) 97.1 (158.2) 0.57 (1.3) 
Diabetes mellitus  
0.330 
 
0.706 
 
0.296 Yes 117.1 (43.2) 110.5 (190.5) 0.58 (1.5) 
No 108.3 (48.2) 105.6 (149.2) 0.78 (2.0) 
Renal failure  
0.003 
 
0.294 
 
0.351 Yes (n=22) 137.9 (35.1) 142.4 (214.9) 0.95 (1.8) 
No (n=99) 105.1 (46.9) 99.4 (149.2) 0.66 (1.9) 
LVSDF  
0.307 
 
0.792 
 
0.093 
Mild LVSDF 107.0 (42.5) 95.6 (156.0) 0.43 (1.0) 
Moderate LVSDF 111.1 (49.7) 119.6 (180.5) 1.1 (2.8) 
Severe LVSDF 125.2 (52.5) 121.6 (158.9) 0.82 (1.7) 
Type of ACS  
0.028 
 
<0.001 
 
<0.001 
STEMI (n=27) 132.2 (58.2) 184.8 (171.5) 1.9 (3.2) 
NSTEMI (n=25) 109.3 (44.8) 118.6 (125.1) 0.91 (1.6) 
UA (n=68) 104.1 (40.1) 72.8 (163.7) 0.15 (0.44) 
Type of STEMI  
0.890 
 
0.488 
 
0.475 
Inferior (n=12) 137.3 (64.5) 144.6 (117.5) 1.1 (1.6) 
Antero Septal (n=3) 146.0 (56.1) 298.3 (192.7) 3.0 (2.7) 
Extensive Anterior (n=10) 126.7 (60.9) 220.3 (219.4) 3.0 (4.7) 
Antero Lateral (n=2) 108.2 (12.1) 79.0 (111.7) 0.15 (0.1) 
SD: Standard deviation; LVSDF: left ventricle systolic dysfunction; ACS: Acute coronary syndromes; STEMI: ST segment elevation 
myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; UA: Unstable angina 
 
 
Figure 1: Receiver operator characteristic curve of PAPP-
A, IGD-1 and Troponin-I for predict STEMI 
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PAPP-A had low accuracy for this prediction. The 
optimum cut-off value for Troponin-I was found to 
be 0.038 with 88% sensitivity and 81% specificity 
(Table 3).  
DISCUSSION 
Although evidence shows the relationship between 
IGF-1 concentration and different components of 
metabolic syndrome and cardiovascular risk 
profile such as body mass index, waist 
circumference and insulin resistance, the value of 
this biomarker for predicting cardiovascular 
events as well as for assessing the type and severity 
of cardiac ischemic events remains challenging 
(24-26). As shown in our study, IGF-1 levels were 
not associated with cardiovascular risk factors. Our 
results showed serum level of IGF-1 was 
significantly higher in patients with STEMI than 
that in patients with UA. Post hoc analysis also 
revealed a significant difference just between UA 
and STEMI. But, ROC curve analysis for IGF-1 was 
not significant for predicting STEMI.  
It has been previously shown that IGF-1 can 
enhance ischemic eventuality, and reduce 
ischemia/reperfusion damage (27). Furthermore, 
expression of IGF-1 in animal models could protect 
cardiovascular system from cardiomyocyte death 
after infarction, and attenuate ventricular dilation, 
wall stress, and cardiac hypertrophy (28, 29). The 
controversy between IGF-1 level and cardiac-
related events in different studies can be attributed 
to factors such as probable effect of genetic 
predisposition. For example, different genetic 
pathways and upregulation of IGF-1 gene in our 
population can produce active form of IGF-1. On the 
other hand, the pathway responsible for activating 
IGF-1 and its effects on cardiac preconditioning and 
plaque stability may be suppressed by some factors 
that should be further assessed.  
Regarding IGF-1 and its relationship with ACS and 
its prognosis, the result of the study by Sekuri et al. 
showed that significantly decreased levels of IGF-1 
in STEMI group of ACS may be used as a diagnostic 
marker for myocardial necrosis, but since no 
relationship existed between IGF-1 level and 
cardiovascular events in 90 days, this parameter 
cannot be suggested as a negative prognostic factor 
(6). 
Yalcin et al. recently revealed that high IGF-1 levels 
may identify the patients who are high-risk for 
stent thrombosis (30). 
Interestingly, in patients with renal failure, IGF-1 
was significantly higher than that in patients 
without renal failure. Regarding the effects of IGF-
1 on ischemic events and plaque vulnerability, it 
was higher just in patients with STEMI than that in 
patients with unstable angina. Several studies 
propose that IGF-1 is involved in the development 
of atherosclerosis, and some of its consequences 
(31, 32). 
In the current study, level of IGF-1 was significantly 
higher in patients with renal failure. Interaction 
between IGF and kidney disease has been 
discussed in two recent studies which confirm our 
results. Bach LA and his colleges showed perturbed 
regulation of the IGF system in a number of kidney 
diseases. Enhanced IGF activity was noted in early 
diabetic nephropathy and polycystic kidneys, but 
IGF resistance was implicated in chronic kidney 
failure (33). In a cohort study by Teppala et al., they 
found higher IGF-1 levels to be positively 
associated with CKD, and suggested assessment of 
serum IGF-1 may be valuable for risk stratification 
of CKD (27). 
As presented in our study, it appears that 
measuring the level of IGF-1 could have a major 
role in predicting adverse events in patients with 
ACS especially renal failure. According to our 
results, the occurrence or uncovering of renal 
failure as a one of main ACS morbidities can be 
predicted by high serum levels of IGF-1. Similarly, 
in Teppala et al. study, higher serum IGF-1 levels 
were positively associated with CKD after adjusting 
for age, sex, race/ethnicity, education levels, 
smoking, alcohol intake, body mass index, diabetes, 
hypertension and serum cholesterol (27). Thus, it 
appears that increasing the level of IGF-1 can be 
helpful to assess tendency to renal failure 
especially in patients with coronary artery disease. 
In our study, there were no significant relationship 
between PAPP-A level and any of cardiac risk 
factors. Also, relationship of this biomarker with 
renal failure was not significant. 
In two recent studies conducted by Konev et al. and 
Table 3: Optimal cut-off point and accuracy with 95% confidence interval (CI) of PAPP-A and Troponin-I for diagnosis of STEMI and 
NSTEMI 
Biomarker Classify group Optimal cut-off point Sensitivity (95% CI) Specificity (95% CI) 
PAPP-A 
STIME-UA 89.2 66.7 (46.0, 83.5) 83.8 (72.9, 91.6) 
NSTIME-UA 95.6 60.0 (38.7, 78.9) 85.3 (74.6, 92.7) 
Troponin-I 
STIME-UA 0.086 85.2 (66.3, 95.8) 86.8 (76.4, 93.8) 
NSTIME-UA 0.038 87.5 (67.6, 97.3) 80.9 (69.5, 89.4) 
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Hjortebjerg et al. it was reported that IGFBP-4 
fragments from PAPP-A were suggested as a novel 
biomarker for cardiac risk assessment (33, 34). 
The relationship between PAPP-A and coronary 
angiographic features in patients with ACS was 
examined in a study by Shehata et al. Higher PAPP-
A levels in patients with ACS were associated with 
unfavorable coronary anatomy and complex 
angiographic plaque features (35). We were not 
able to assess angiographic features of study group. 
Literature review about PAPP-A and ACS or cardiac 
events shows similar results. In this context, 
Bonaca et al. conducted a study of usefulness of 
PAPP-A for risk assessment in NSTEMI. PAPP-A 
was independently associated with recurrent 
cardiovascular events in these patients. So, they 
suggest PAPP-A as a candidate prognostic marker 
in patients with ACS (36). 
Our study revealed a significant association 
between serum level of PAPP-A and type of ACS and 
also post hoc analysis showed a significant 
difference between UA and STEMI. In a similar 
study by Gururajan et al., PAPP-A had a pivotal role 
in the pathogenesis of atherosclerosis. PAPP-A 
level was higher in patients diagnosed as ACS in 
comparison with the controls. PAPP-A was able to 
differentiate ischemic and non-ischemic patients. 
AUC was 0.904, 95% CI (0.874–0.929) with 85% 
specificity and 90% sensitivity (P < 0.0001). The 
acquired cut-off value was 0.55 μg/mL, and above 
this value, PAPP-A was regarded to be positive 
(37). In line with our study, Laterza et al. reported 
cut-off value of 0.22 mIU/L, with a sensitivity of 
66.7% and a specificity of 51.1% for PAPP-A to be 
a predictor of adverse events at 30 days, but it was 
inferior to cardiac Troponin-I (38). Detailed 
clarification of the pathophysiologic role of PAPP-A 
in detecting STEMI (myocardial necrosis) could be 
promising for the innovation of specific biomarker-
directed therapies. 
Limitations 
Our study has limitations that warrant 
consideration. These limitations originate mainly 
from the inclusion of the in-hospital period without 
long-term follow-up, failure to consider 
angiographic data, and lack of a healthy population 
as the control group. Further studies are 
recommended for long-term follow-up of patients, 
comparing IGF-1 and PAPP-A levels between 
patients with ACS and a control group, analysis of 
angiographic data including involved coronary 
artery, Gensini score, syntax score, need to 
revascularization and finally determining 
correlation of these parameters with IGF-1 and 
PAPP-A levels. 
CONCLUSIONS 
In summary, it appears measuring serum level of 
PAPP-A could predict STEMI in patients with ACS. 
Serum level of IGF-1 is not able to predict STEMI in 
cases admitted for ACS. Regarding higher IGF-1 
levels in these patients with CKD, this biomarker 
may be valuable for cardiac risk stratification of 
CKD, but further studies are necessary to clarify 
this point. 
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